SecBot SecBot
8-K ·Filed Aug 11, 2026

APGE

Apogee Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001140361-26-032231
8-K context-dependent: Items 5.02
Actionable Insight ▲ Bullish

The shareholder vote removes the last major regulatory/approval hurdle for the AbbVie acquisition. The deal is now subject to remaining antitrust clearances (Australia ACCC) and customary closing conditions. Traders should monitor for the final regulatory sign-offs and the expected closing date; the stock should trade near the $135.11 offer price minus any remaining risk premium.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$134.55
T+0 close · Aug 11, 2026 · via day close
Latest settled
+0.12%
T+5 · $134.71
Vs SPY
+0.56%
α at T+5
Next horizon
T+20
due 2mo ago
  1. T+0 · Aug 12 $134.55entry
  2. T+1 · 3mo ago −0.07%α −0.77% · $134.45
  3. T+5 · 3mo ago +0.12%α +0.56% · $134.71
  4. T+20 · due 2mo ago Pending
  5. T+60 · due 12d ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics stockholders voted overwhelmingly to approve the $135.11/share all-cash acquisition by AbbVie, with 46,508,107 votes for and only 3,885 against, satisfying a key closing condition. The board also disclosed that all seven directors intend to resign effective at the merger's closing, a routine step in a change-of-control transaction. The non-binding advisory vote on executive merger-related compensation was rejected, but this does not affect deal consummation. The merger remains on track with German antitrust clearance already obtained and an Australian filing underway.

Key Facts

  • Stockholders approved the merger proposal with 46,508,107 votes for, 3,885 against, and 14,261 abstentions.
  • All seven directors (Michael Henderson, Mark C. McKenna, Lisa Bollinger, Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak, Nimish Shah) intend to resign effective at the merger closing.
  • The non-binding advisory vote on executive merger compensation was not approved (19,323,605 for, 27,123,259 against), but this is not a condition to closing.
  • The merger is an all-cash acquisition by AbbVie at $135.11 per share, valuing Apogee at approximately $8.4B based on 62,140,183 voting shares outstanding.
  • German antitrust clearance (FCO) was obtained on July 27, 2026, and an Australian ACCC filing is underway.

Financial Impact

All-cash acquisition at $135.11/share, valuing Apogee at approximately $8.4B based on 62,140,183 voting shares outstanding.

dealValue

Risk Factors

  • Remaining antitrust clearances (Australia ACCC) could delay closing.
  • The non-binding compensation vote rejection signals potential shareholder dissent, though it does not block the deal.
  • Any unexpected regulatory or litigation developments could delay or derail the merger.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
33% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-032231
Document: 0001140361-26-032231-index-headers.html0001140361-26-032231
Document: 0001140361-26-032231-index.html0001140361-26-032231
Document: 0001140361-26-032231.txt0001140361-26-032231

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Viewing Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (9h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026